You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Exon 20 Insertion Mutations

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

NSCLC Trial (Mobocertinib 160 mg)

Approved for marketing
  • Carcinoma, Non-Small-Cell Lung
  • Mobocertinib 160 mg
  • (no location specified)
Sep 28, 2022

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

NSCLC Trial in Changsha (BEBT-109)

Completed
  • NSCLC
  • Changsha, Hunan, China
    Hunan Cancer hospital
Aug 20, 2023

A Chart Review Study of Adults With Advanced NSCLC

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
    • (no location specified)
    Aug 1, 2022

    Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

    Recruiting
    • Lung Neoplasm Malignant
    • +18 more
    • Fairfax, Virginia
      New Experimental Therapeutics of Virginia (NEXT Oncology)
    Mar 29, 2022

    Locally Advanced or Metastatic NSCLC, EGFR Exon20 Insertion Mutations Trial (JMT101, Osimertinib Mesylate Tablets)

    Not yet recruiting
    • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    • EGFR Exon20 Insertion Mutations
    • JMT101
    • Osimertinib Mesylate Tablets
    • (no location specified)
    Nov 12, 2021

    Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

    Recruiting
    • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 21, 2023

    Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

    Recruiting
    • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
    • Canton, Ohio
      Gabrail Cancer and Research Center
    Jul 25, 2023

    Non-small Cell Lung Cancer EGFR Exon 20 Insertion

    Recruiting
    • Non-small Cell Lung Cancer (NSCLC)
      • Cordoba, Andalucia, Spain
      • +14 more
      Nov 1, 2022

      Metastatic NSCLC Trial (Amivantamab)

      Approved for marketing
      • Metastatic Non-Small Cell Lung Cancer
      • (no location specified)
      Jun 28, 2021

      Non Small Cell Lung Cancer, EGFR Exon 20 Mutation Trial in Worldwide (CLN-081)

      Recruiting
      • Non Small Cell Lung Cancer
      • EGFR Exon 20 Mutation
      • Duarte, California
      • +18 more
      Nov 11, 2022

      Osimertinib for Patients With Non-Small Cell Lung Cancer

      Not yet recruiting
      • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
      • EGFR Exon20 Insertion Mutations
      • Baoding, China
      • +23 more
      Aug 23, 2022

      NSCLC (NSCLC) Trial (TAK-788, Antidiarrheal prophylaxis)

      Withdrawn
      • Non-Small Cell Lung Cancer (NSCLC)
      • (no location specified)
      Dec 15, 2020

      Advanced/Metastatic NSCLC (NSCLC) Trial in China (YK-209A tablet, Pemetrexed+carboplatin/Cisplatin)

      Not yet recruiting
      • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
      • Bengbu, Anhui, China
      • +51 more
      Mar 11, 2023

      NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC Trial in Canada, Hong Kong, United States (tarloxotinib bromide)

      Terminated
      • NSCLC, Stage IV
      • +7 more
      • tarloxotinib bromide
      • Irvine, California
      • +13 more
      Nov 11, 2021

      NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +13 more
      • furmonertinib 240 mg
      • +2 more
      • Yuma, Arizona
      • +37 more
      Dec 14, 2022

      NSCLC Trial in Winter Haven (Poziotinib, Docetaxel)

      Suspended
      • NSCLC
      • Winter Haven, Florida
        Bond Clinic, P.A.
      Jan 27, 2023

      NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

      Recruiting
      • NSCLC
      • Furmonertinib 160mg
      • Furmonertinib 240mg
      • Shanghai, China
        Shanghai Chest hospital
      Jan 16, 2023

      NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

      Recruiting
      • Non-Small Cell Lung Cancer
      • +5 more
      • Toripalimab
      • +3 more
      • Guanzhou, Guangdong, China
        Guangdong Lung Cancer Institute, Guangdong Provincial People's H
      Apr 4, 2023

      Locally Advanced or Metastatic NSCLC Trial in Seoul (Osimertinib 80 MG [Tagrisso])

      Completed
      • Locally Advanced or Metastatic NSCLC
      • Osimertinib 80 MG [Tagrisso]
      • Seoul, Korea, Republic of
        Seoul National University Hospital
      Sep 22, 2021

      Locally Advanced or Metastatic NSCLC Trial in China (JMT101)

      Unknown status
      • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
      • Guangzhou, Guangdong, China
      • +12 more
      Dec 23, 2020

      Learn About Tests Looking forGene Mutation in Lung Cancer in

      Not yet recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • No Intervention
      • Beijing, China
        Department of Pathology, National Cancer Center/National Clinica
      Feb 24, 2023

      Non-squamous NSCLC Trial (biological, drug, dietary supplement)

      Not yet recruiting
      • Non-squamous NSCLC
      • Pembrolizumab
      • +7 more
      • (no location specified)
      Feb 20, 2023

      Mobocertinib in Adults With Lung Cancer in China (MEANING)

      Not yet recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • No Intervention
      • Shanghai, China
        Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai J
      May 9, 2023